Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment
ConclusionsThe developed NLC proved to be a promising formulation with which to overcome the drawbacks of current leishmaniasis treatment by the co-delivery of two alternative drugs and a macrophage targeting modified surface.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
More News: Antimicrobial Resistance | Bactrim | HIV-Leishmania Co-infection | Infectious Diseases | Nanotechnology | Polymyxin B | Study